The Medical Letter on Drugs and Therapeutics
ONLINE
ONLY
ARTICLE
January 23, 2023
View Complete Issue         Table of Contents 2019 
Opdualag for Metastatic Melanoma (online only)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Opdualag for Metastatic Melanoma (online only)
January 23, 2023 (Issue: 1668)
Opdualag (BMS), a fixed-dose combination of two immune checkpoint inhibitors — nivolumab (Opdivo), a programmed death receptor-1 (PD-1) inhibitor, and relatlimab-rmbw, a lymphocyte-activation gene-3 (LAG-3) blocking antibody — has been...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Opdualag for Metastatic Melanoma (online only)
Article code: 1668g
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.